SAUDI ARABIA PHARMACEUTICAL DRUGS MARKET ANALYSIS

Saudi Arabia Pharmaceutical Drugs Market, By Drug Type (Generic Drugs and Branded Drugs), By Product Type (Prescription Drugs and Over-the-counter (OTC) Drugs), By Application (Cardiovascular, Musculoskeletal, Oncology, Anti-infective, Metabolic Disorder, Central Nervous System, Gastrointestinal, Respiratory, Hematology, Dermatology, Ophthalmology, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Saudi Arabia Pharmaceutical Drugs Market: Key Developments

In August 2023, Daewoong Pharmaceutical Co., a South Korea-based pharmaceutical company, announced that it had submitted an application for regulatory approval of its new diabetes treatment drug Envlo tablet (active ingredient: enavogliflozin) to the Saudi Food and Drug Authority (SFDA).
In June 2022, Astellas Pharma, a global pharmaceutical company, announced the official inauguration of its newly established Scientific and Technical Office in Riyadh. The office opening is part of Astellas’ long-term commitment to the Kingdom and stems from the company’s strong belief in leveraging technology to better serve local patients and communities; and support the local healthcare infrastructure with innovative medicines and treatments.
In November 2023, BeiGene, a global, science-driven biotechnology company, and NewBridge Pharmaceuticals, a specialty company in the Middle East and North Africa (MENA) regions, announced that BRUKINSA (zanubrutinib) had received approval from the Saudi Food and Drug Authority (SFDA) for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy.